Thomas P, Doddoli C, Yena S, Thirion X, Sebag F, Fuentes P, Giudicelli R
Department of Thoracic Surgery, Sainte Marguerite Hospital-CHU Sud, Université Méditerranée (Aix-Marseille II), School of Medicine, 270 Bd Sainte Marguerite, France.
Eur J Cardiothorac Surg. 2002 Jun;21(6):1094-9. doi: 10.1016/s1010-7940(02)00179-3.
This study was designed to determine the long-term prognosis of video-assisted thoracic surgery (VATS) vs. open lung resections for patients with pathological stage I non-small cell lung cancer (NSCLC).
The medical records of all patients who underwent lung resection for a pathological stage I NSCLC were reviewed for the period from 1990 to 1999, by screening of a database into which data were entered prospectively. There were 511 patients (430 males and 81 females) whose age averaged 63+/-10 years who underwent 515 lung resections. Our VATS experience began in 1993 with selected stage I patients, and since that date an average of one patient on four was managed with VATS. Lung resections consisted of 25 wedge resections or segmentectomies (seven VATS), 390 lobectomies (92 VATS), 19 bilobectomies (one VATS) and 81 pneumonectomies (ten VATS). Lymph node dissection was performed in all cases.
There were significantly more females (P=0.01) and adenocarcinoma (P=0.02) in the VATS group (n=110) when compared to the open group (n=405). Tumour size averaged 4+/-2 cm in the open group and 3+/-2 cm in the VATS group (P=0.04). The distribution of T1/T2 tumours was 97/308 and 50/60, respectively (P=0.0001). At follow-up, cancer recurrence could be documented in 117 patients, with no difference of incidence between the two groups (22.5 vs. 24.5%; P=0.64). Estimated Kaplan-Meier 5-year survival rates, including the operative mortality as well as any cancer-related and unrelated death, were 62.8% (confidence interval (CI): 56.8-68.7%) vs. 62.9% (CI: 51.4-74.4%), respectively (P=0.60). The advent of VATS did not influence the patients' survival: 5-year survival rate was 63.9% (CI: 55.3-72.5%) for the period from 1990 to 1992, and 58.8% (CI: 51.7-65.9%) for the period from 1993 to 1999 (P=0.65). Subgroups survival analysis according to the T status did not show any statistically significant difference between the two groups.
VATS lung resection with lymph node dissection achieved a 5-year survival similar to that achieved by the conventional approach. VATS is a valuable option for the management of selected patients with an early-stage NSCLC.
本研究旨在确定电视辅助胸腔镜手术(VATS)与开胸肺切除术治疗病理I期非小细胞肺癌(NSCLC)患者的长期预后。
通过筛查前瞻性录入数据的数据库,回顾了1990年至1999年期间所有因病理I期NSCLC接受肺切除术患者的病历。共有511例患者(430例男性和81例女性),平均年龄63±10岁,接受了515例肺切除术。我们的VATS经验始于1993年,最初选择I期患者,自那时起平均每4例患者中有1例采用VATS治疗。肺切除术包括25例楔形切除术或肺段切除术(7例VATS)、390例肺叶切除术(92例VATS)、19例双叶切除术(1例VATS)和81例全肺切除术(10例VATS)。所有病例均进行了淋巴结清扫。
与开胸组(n = 405)相比,VATS组(n = 110)女性患者(P = 0.01)和腺癌患者(P = 0.02)明显更多。开胸组肿瘤平均大小为4±2 cm,VATS组为3±2 cm(P = 0.04)。T1/T2肿瘤的分布分别为97/308和50/60(P = 0.0001)。随访时,117例患者有癌症复发记录,两组发病率无差异(22.5%对24.5%;P = 0.64)。包括手术死亡率以及任何与癌症相关和无关的死亡在内,估计的Kaplan-Meier 5年生存率分别为62.8%(置信区间(CI):56.8 - 68.7%)和62.9%(CI:51.4 - 74.4%)(P = 0.60)。VATS的出现并未影响患者的生存率:1990年至1992年期间5年生存率为63.9%(CI:55.3 - 72.5%),1993年至1999年期间为58.8%(CI:51.7 - 65.9%)(P = 0.65)。根据T分期进行的亚组生存分析显示两组之间无统计学显著差异。
VATS肺切除术加淋巴结清扫术的5年生存率与传统方法相似。VATS是治疗部分早期NSCLC患者的一种有价值的选择。